NCT03172936 - Study of the Safety and Efficacy of MIW815 With PDR001 in Patients With Advanced/Metastatic Solid Tumors or Lymphomas | Biotech Hunter

Enrollment

106

Participants

Timeline

Start Date

September 8, 2017

Primary Completion Date

December 18, 2020

Study Completion Date

December 18, 2020

Conditions

Solid Tumors and Lymphomas

Interventions

DRUG

MIW815

MIW 815 (ADU-S100) is a STING agonist

BIOLOGICAL

PDR001

PDR001 is an anti-PD-1 antibody

Trial Locations (12)

Novartis Investigative Site, North Sydney

Novartis Investigative Site, Melbourne

Novartis Investigative Site, Zurich

Novartis Investigative Site, Essen

Novartis Investigative Site, Chicago

MD Anderson Cancer Center, Houston

The Angeles Clinic and Research Institute, Los Angeles

Seattle Cancer Care Alliance, Seattle

Novartis Investigative Site, Toronto

Novartis Investigative Site, Chuo Ku

Novartis Investigative Site, Amsterdam

Novartis Investigative Site, L'Hospitalet de Llobregat